Browsing Clinical Studies by author "Slater, Susanna"
Now showing items 1-3 of 3
-
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater, S; Bryant, A; Chen, H-C; Begum, R; Rana, I; et al. (BMC, 2023-03-20)BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk ... -
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas, S; Chamberlain, F; Carter, T; Slater, S; Cojocaru, E; et al. (BMC, 2020-05-06)BACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin ... -
The Role of ctDNA in Gastric Cancer.
Mencel, J; Slater, S; Cartwright, E; Starling, N (MDPI, 2022-10-18)Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting ...